475 results
Featured research - Tricuspid valve intervention: latest advanced insights
17 Nov 2025 – From PCR London Valves 2025
This featured research session delves into advanced insights on tricuspid valve interventions, focusing on the significance of right ventricular function and dimension in patient outcomes. It explores prognostic factors such as right ventricular loading mismatch, innovations like the clover technique in Pascal TEER, myocardial work recovery,...
Pulmonary valve interventions
17 Nov 2025 – From PCR London Valves 2025
This session presents complex cases and innovative solutions in pulmonary valve interventions. It highlights a novel balloon-expandable valve for the right ventricular outflow tract, management of severe prosthetic pulmonary valve stenosis in congenital heart disease, approaches to residual lesions in Fallot's anomaly, treatment of double outlet...
From innovation to intervention: optimising procedural techniques in tricuspid TEER
17 Nov 2025 – From PCR London Valves 2025
Explore advanced strategies for tricuspid TEER in this PCR London Valves 2025 session.
Through real-world cases and interactive simulation, learn how to optimise outcomes in complex tricuspid anatomy, manage challenges posed by pacemaker leads, and enhance procedural efficiency using the TriClip G5 device.
Gain practical insights on clipping...
Tricuspid repair or replacement - Matching the patient to the procedural strategy
17 Nov 2025 – From PCR London Valves 2025
This session addresses the nuanced decision-making process in selecting appropriate transcatheter tricuspid repair or replacement strategies. It covers the current device landscape, patient selection criteria based on anatomical and clinical factors, and discusses emerging challenges such as pacing lead management, anticoagulation, and outcome definitions.
Tricuspid interventions: knowns and unknowns
17 Nov 2025 – From PCR London Valves 2025
Explore the evolving landscape of transcatheter tricuspid valve interventions in this session, which presents the latest evidence from registries and randomized trials. Discussions include the new Euro tricuspid regurgitation risk score, clinical controversies, real-world patient scenarios, and insights into optimal medical therapy and device selection to...
Featured research - Tricuspid valve intervention: the TRIPLACE registry
17 Nov 2025 – From PCR London Valves 2025
This session features cutting-edge research on tricuspid valve interventions, including insights from the TRIPLACE registry on orthotopic TTVR thrombosis, predictive value of three-dimensional tricuspid annulus measurements for procedural outcomes, early clinical experiences with novel TTVR systems, and procedural clipping strategies based on results from the BRIGHT...
Early Career Research Award Final
17 Nov 2025 – From PCR London Valves 2025
Highlighting pioneering research in structural heart interventions, this session presents studies on the impact of transcatheter tricuspid valve replacement (TTVR) on left ventricular geometry and function, myocardial remodeling in aortic stenosis, physiological responses after mitral and tricuspid edge-to-edge repairs, advancing the understanding of device effects on...
TTVR - Part 2
17 Nov 2025 – From PCR London Valves 2025
This session presents advances in transcatheter tricuspid valve replacement (TTVR), highlighting cases such as Evoque valve implantation post-cardioband, TTVR following valve annuloplasty in amyloidosis, rescue interventions after edge-to-edge repair failure, and management of complex anatomical challenges including left inferior vena cava and lead interference in high-risk...
TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation
16 Nov 2025 – From PCR London Valves 2025
Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.
TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...
Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?
17 Nov 2025 – From PCR London Valves 2025
Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends...
